SEC Form 4 · accession 0001144204-18-065469
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Shapiro
Officer — Chief Medical Officer
Period of report
Dec 17, 2018
Accepted (ET)
Dec 19, 2018 · 7:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 17, 2018 | M | 2,000 | $31.90 | A | 41,152 | D | |
| Common Stock | Dec 17, 2018 | S | 2,000 | $106.62 | D | 39,152 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $31.90 | Dec 17, 2018 | M | 2,000 | D | — | May 7, 2023 | Common Stock | 2,000 | 19,031 | D |
Explanation of responses
- F1This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- F2This option is fully vested and exercisable.